2020
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino K, Park T, Ahuja N. Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. Seminars In Cancer Biology 2020, 65: 114-122. PMID: 31911188, DOI: 10.1016/j.semcancer.2020.01.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsResponse ratePeripheral T-cell lymphomaTriple-negative breast cancerLarge B-cell lymphomaDurable response rateEffective standard therapyDeath protein 1Solid organ tumorsInhibitory immune receptorsT-cell lymphomaNegative breast cancerB-cell lymphomaAdvanced malignanciesMost patientsStandard therapyClinical efficacyCommon malignancyHepatobiliary cancersTherapeutic optionsNeck cancerOrgan tumorsInitial respondersOvarian cancerProstate cancerBreast cancer
2017
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clinical Cancer Research 2017, 23: 2691-2701. PMID: 27979916, PMCID: PMC5457329, DOI: 10.1158/1078-0432.ccr-16-1729.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerObjective response rateCombination epigenetic therapyEstrogen receptorEndocrine therapyPrimary endpointPartial responseMulticenter phase II studyEpigenetic therapyAdditional partial responsesHormone-resistant diseasePhase II studyTime of progressionBreast cancer modelClin Cancer ResHistone deacetylase inhibitorsImportant therapeutic targetPosttreatment biopsiesTNBC cohortII studyBreast cancerDNA methyltransferase inhibitorTherapeutic targetResponse rateCancer modelEpigenetic therapy and chemosensitization in solid malignancy
Ronnekleiv-Kelly SM, Sharma A, Ahuja N. Epigenetic therapy and chemosensitization in solid malignancy. Cancer Treatment Reviews 2017, 55: 200-208. PMID: 28431263, DOI: 10.1016/j.ctrv.2017.03.008.Peer-Reviewed Original ResearchConceptsCombination therapyEpigenetic therapySpecific hematologic malignanciesCertain solid tumorsHistone deacetylase inhibitorsDurable responsesSystemic therapyPatient subsetsSolid malignanciesHematologic malignanciesOvarian cancerBreast cancerDNA methyltransferase inhibitorEpigenetic changesSolid tumorsDeacetylase inhibitorsStandard chemotherapeuticsTherapyClinical potentialCancer cellsTrialsNSCLCMalignancyMethyltransferase inhibitorHypermethylation patterns
2014
Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer.
Connolly R, Jankowitz R, Zahnow C, Zhang Z, Rudek M, Slater S, Powers P, Jeter S, Brufsky A, Piekarz R, Herman J, Ahuja N, Somlo G, Garcia A, Baylin S, Davidson N, Stearns V. Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer. Journal Of Clinical Oncology 2014, 32: 569-569. DOI: 10.1200/jco.2014.32.15_suppl.569.Peer-Reviewed Original Research
2012
Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen
Jeschke J, Van Neste L, Glöckner SC, Dhir M, Calmon MF, Deregowski V, Van Criekinge W, Vlassenbroeck I, Koch A, Chan TA, Cope L, Hooker CM, Schuebel KE, Gabrielson E, Winterpacht A, Baylin SB, Herman JG, Ahuja N. Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 2012, 7: 701-709. PMID: 22647880, DOI: 10.4161/epi.20445.Peer-Reviewed Original ResearchConceptsPoor overall survivalBreast cancerOverall survivalPrognosis predictionEffective biomarkersClinical prognostic variablesPrimary breast cancerDetection of BCFrequent methylated genesStrongest single markersSignificant prognosticatorBC patientsValidation cohortPrognostic variablesPrognostic signatureEarly detectionCancerBiomarkersPromoter hypermethylationMethylation changesTumor heterogeneityPrognosisSingle markerGene expression approachSurvival
2011
OT3-01-06: A Phase 2 Study Investigating the Safety, Efficacy and Surrogate Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat (MS-275) in Patients with Advanced Breast Cancer.
Connolly R, Jankowitz R, Andreopoulou E, Allred J, Jeter S, Zorzi J, Adam B, Espinoza-Delgado I, Baylin S, Zahnow C, Ahuja N, Davidson N, Stearns V. OT3-01-06: A Phase 2 Study Investigating the Safety, Efficacy and Surrogate Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat (MS-275) in Patients with Advanced Breast Cancer. Cancer Research 2011, 71: ot3-01-06-ot3-01-06. DOI: 10.1158/0008-5472.sabcs11-ot3-01-06.Peer-Reviewed Original ResearchObjective response rateHistone deacetylase inhibitorsHormone-resistant diseaseAdvanced breast cancerBreast cancerDNA methyltransferase inhibitorHormonal therapyAdvanced human epidermal growth factor receptor 2Response rateMulticenter phase II studyHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Adequate organ functionClinical benefit rateRECIST 1.1 criteriaPhase II studyWeeks of therapyPhase 2 studyProgression-free survivalGrowth factor receptor 2Objective disease responseNegative breast cancerFactor receptor 2Important therapeutic targetCandidate gene methylation
2007
The Role of Ultrasound-Guided Fine-Needle Aspiration of Axillary Nodes in the Staging of Breast Cancer
Jain A, Haisfield-Wolfe ME, Lange J, Ahuja N, Khouri N, Tsangaris T, Zhang Z, Balch C, Jacobs LK. The Role of Ultrasound-Guided Fine-Needle Aspiration of Axillary Nodes in the Staging of Breast Cancer. Annals Of Surgical Oncology 2007, 15: 462-471. PMID: 17985188, DOI: 10.1245/s10434-007-9623-1.Peer-Reviewed Original ResearchConceptsUltrasound-guided fine-needle aspirationSentinel node dissectionAxillary node dissectionPreoperative ultrasound-guided fine-needle aspirationPositive predictive valuePrimary tumor featuresFine-needle aspirationAxillary nodesNode dissectionTumor featuresAbnormal axillary nodesBreast cancer patientsLymph node pathologyPrimary breast tumorsRole of ultrasoundSuspicious nodesNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseDefinitive managementCancer patientsBreast cancerPredictive valueBreast tumorsUSFNA results